Evidence map›Paper›PMID 39619352›Full record

ArticlePsychiatry and clinical psychopharmacology2021

Decrease in Serum Lithium Levels Induced by Ursodeoxycholic Acid: A Case Report.

Gizem Gulpamuk, Kursat Altinbas

Abstract read
In one paragraph

Article in Psychiatry and clinical psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gizem GulpamukDepartment of Psychiatry, Selcuk University, Konya, Turkey.ORCID 0000-0001-8189-930X
Kursat AltinbasDepartment of Psychiatry, Selcuk University, Konya, Turkey.ORCID 0000-0003-2899-0096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lithium is a leading therapeutic option for bipolar patients in the treatment of acute and maintenance phases of illness. Lithium levels should be closely monitored due to its narrow therapeutic index. Combination of other treatment regimens with lithium may increase or decrease lithium levels that may cause intoxication symptoms or recurrence of mood episodes. Therefore, clinicians should be aware of the drugs recommended by other medical specialties that may change lithium plasma levels. Nonsteroidal anti-inflammatory drugs, thiazide diuretics, and angiotensin-converting enzyme inhibitors are the best known potential medicines for drug interactions with lithium. In this article, we aimed to present a case report of a patient who was taking lithium for recurrent depression more than 3 years with stable serum levels, but lithium levels decreased fastly after the prescription of ursodeoxycholic acid. The possible mechanism of interaction between lithium and ursodeoxycholic acid was discussed with the current literature.

Indexed as

Bipolar disorderlithiumursodeoxycholic acid

Identifiers

PMID39619352
PMCPMC11605312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.